IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism.
Publication/Presentation Date
9-1-2023
Abstract
Therapy using anti-PD-1 immune checkpoint inhibitors (ICI) has revolutionized the treatment of many cancers including head and neck squamous cell carcinomas (HNSCC), but only a fraction of patients respond. To better understand the molecular mechanisms driving resistance, we performed extensive analysis of plasma and tumor tissues before and after a 4-week neoadjuvant trial in which HNSCC patients were treated with the anti-PD-1 inhibitor, nivolumab. Luminex cytokine analysis of patient plasma demonstrated that HPV
Volume
62
Issue
9
First Page
1428
Last Page
1443
ISSN
1098-2744
Published In/Presented At
Hill, B. L., Calder, A. N., Flemming, J. P., Guo, Y., Gilmore, S. L., Trofa, M. A., Daniels, S. K., Nielsen, T. N., Gleason, L. K., Antysheva, Z., Demina, K., Kotlov, N., Davitt, C. J. H., Cognetti, D. M., Prendergast, G. C., Snook, A. E., Johnson, J. M., Kumar, G., Linnenbach, A. J., Martinez-Outschoorn, U., … Mahoney, M. G. (2023). IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism. Molecular carcinogenesis, 62(9), 1428–1443. https://doi.org/10.1002/mc.23587
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
37401875
Department(s)
Administration and Leadership
Document Type
Article